CN105759056A - Lung cancer screening kit - Google Patents
Lung cancer screening kit Download PDFInfo
- Publication number
- CN105759056A CN105759056A CN201610210301.6A CN201610210301A CN105759056A CN 105759056 A CN105759056 A CN 105759056A CN 201610210301 A CN201610210301 A CN 201610210301A CN 105759056 A CN105759056 A CN 105759056A
- Authority
- CN
- China
- Prior art keywords
- reagent
- cerberus
- lung cancer
- expression
- detecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 51
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 26
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 26
- 238000012216 screening Methods 0.000 title claims abstract description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 55
- 241000202252 Cerberus Species 0.000 claims abstract description 46
- 102100025745 Cerberus Human genes 0.000 claims description 45
- 101710010675 Cerberus Proteins 0.000 claims description 45
- 238000001514 detection method Methods 0.000 claims description 30
- 238000012360 testing method Methods 0.000 claims description 11
- 210000002966 serum Anatomy 0.000 claims description 9
- 238000002965 ELISA Methods 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 238000001262 western blot Methods 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 description 18
- 238000005406 washing Methods 0.000 description 14
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
- 239000008367 deionised water Substances 0.000 description 8
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229960002685 biotin Drugs 0.000 description 6
- 235000020958 biotin Nutrition 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- 239000000385 dialysis solution Substances 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000010355 oscillation Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003147 molecular marker Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000269417 Bufo Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a lung cancer screening kit, which comprises an optional reagent for detecting the expression level of Cerberus. The invention also discloses application of the reagent for detecting the expression level of Cerberus in preparing a reagent for screening lung cancer. The kit can judge the risk of lung cancer of the people to be detected by detecting the expression level of Cerberus, can be used for auxiliary diagnosis of clinical lung cancer, provides effective basis for patients to take relevant treatment measures or decisions, and has good clinical application prospect.
Description
Technical field
The present invention relates to a kind of screening lung cancer test kit.
Background technology
Pulmonary carcinoma is one of modal malignant tumor in the world, and its M & M is in ascendant trend year by year, and current sickness rate occupies first place in the world, and human health and life in serious threat.
The cause of disease of pulmonary carcinoma is complicated, it is considered that influence factor includes: 1. smoking；2. environmental pollution: such as haze, interior decoration；3. bad life style: as poor in dietary habit, life stress is big；4. chronic lung disease: such as pulmonary tuberculosis, pneumoconiosis, pneumosilicosis, chronic bronchitis；5. human body intrinsic factor: such as Inheritance, immune function reduction, endocrine function imbalance etc..
Meanwhile, pulmonary carcinoma is a kind of disease being good at concealment, just shows clinical symptoms to late period through disease progression of being everlasting, the patients with lung cancer of 70～80% when being diagnosed as Lung Cancer Symptoms be in, late period, cancerous cell spreads, and misses best healing opportunity, and five year survival rate is low.For the patients with lung cancer of early stage, through timely 5 years and above survival rate and life quality treated and be greatly improved patient.Therefore the early diagnosis of pulmonary carcinoma and to carry out effective examination most important.
The examination of pulmonary carcinoma, refers to and does not have the related indication crowd of pulmonary carcinoma to carry out routine physical examination those, find pulmonary carcinoma before there is symptom in time.If the pulmonary carcinoma molecular marker inside blood can be found, for pointing out clinician's early stage that patient takes the remedy measures being correlated with or decision-making have great importance.
Cerberus, also known as Cerberus1, CER-1, is separate to obtain in the Bufo siccus body of Africa the earliest, is a kind of Wnt signal path antagonist, and Cerberus is by being directly connected thus stoping Wnt to be connected with receptor protein complex with Wnt albumen.Have no the report relevant to pulmonary carcinoma about Cerberus at present.
Summary of the invention
In order to solve the problems referred to above, pulmonary carcinoma is studied in detail by inventor, it was found that Cerberus can as its molecular marker.Wherein, Cerberus expression in serum and pulmonary carcinoma are proportionate.Therefore, by detecting the expression of Cerberus in serum, it is possible to predict the risk that crowd to be checked suffers from pulmonary carcinoma.
Accordingly, the invention provides a kind of screening lung cancer test kit and the purposes that the reagent of the expression of detection Cerberus is in preparing screening lung cancer reagent.
The screening lung cancer test kit of the present invention, it includes the optional reagent for detecting Cerberus expression.
Wherein, described reagent is for detecting the reagent of Cerberus expression in serum.
Wherein, the reagent of described detection Cerberus expression is protein chip detection method reagent.
Wherein, the reagent of described detection Cerberus expression is ELISA detection method reagent or WesternBlot detection method reagent.
Present invention also offers the reagent of detection Cerberus expression purposes in preparing screening lung cancer reagent.
Wherein, described reagent is for detecting the reagent of Cerberus expression in serum.
Wherein, the reagent of described detection Cerberus expression is protein chip detection method reagent.
Wherein, the reagent of described detection Cerberus expression is ELISA detection method reagent or WesternBlot detection method reagent.
Test kit of the present invention is by detecting the expression of Cerberus, may determine that the risk that crowd to be checked suffers from pulmonary carcinoma: if the expression of Cerberus is high, the risk then suffering from pulmonary carcinoma is high, if the expression of Cerberus is low, the risk then suffering from pulmonary carcinoma is low, can be used for the auxiliary diagnosis of clinical pulmonary carcinoma, potential applicability in clinical practice is good.
Obviously, the foregoing according to the present invention, according to ordinary technical knowledge and the customary means of this area, without departing under the above-mentioned basic fundamental thought premise of the present invention, it is also possible to make the amendment of other various ways, replacement or change.
The detailed description of the invention of form by the following examples, is described in further detail the foregoing of the present invention again.But this should not being interpreted as, the scope of the above-mentioned theme of the present invention is only limitted to Examples below.All technology realized based on foregoing of the present invention belong to the scope of the present invention.
Accompanying drawing explanation
Fig. 1 is early stage of lung cancer patient and normal healthy controls plasma C erberus testing result figure
Detailed description of the invention
The relation of embodiment 1Cerberus expression and pulmonary carcinoma
Experimental technique is as follows:
One, clinical data
Choosing early stage of lung cancer patient 15 example, normal healthy controls 10 example, essential information is as follows:
| Essential information | Patients with lung cancer | Normal healthy controls |
| Number | 15 | 10 |
| Age | 61.2±12.2 | 49.5±10.6 |
| Masculinity proportion | 10 (66.7%) | 6 (60.0%) |
Two, the detection (content of detection by quantitative Cerberus) of Cerberus expression
Adopt the AAH-BLG-CUST test kit (article No.: AAH-BLG-CUST) bought in RayBiotech company, detect the expression of Cerberus as follows:
1, sample dialysis
Extract the blood of patients with lung cancer and normal healthy controls, after EDTA anticoagulant centrifugal (1200rpm, 10min), carry out second time centrifugal (3000rpm, 15min) by after supernatant absorption, draw the supernatant after second time is centrifuged and blood plasma, as detection specimen ,-80 DEG C of preservations after subpackage.
Plasma sample needs to utilize Dialysis tubing to dialyse before biotin labeling.Separately sampled product 100 μ L joins in Dialysis tubing, then in the 1 × PBS (pH=8) of 4000mL 4 DEG C dialyse while stirring.Dialysis solution is changed once in interval 3 hours, and collection sample of dialyse after three times is to 1.5mL centrifuge tube.
The preparation of note: 1 × PBS: 1.0gKCl, 40gNaCl, 1.0gKH2PO4,5.75gNa2HPO4, with 4,500ml deionized water dissolving, regulate pH=8.0 with 1MNaOH, is finally settled to 5,000ml with deionized water.
2, biotin labeling sample
Process at whole biotin labeling sample, it is to avoid any reagent is subject to the pollution of amine substance or sodium azide.
1) before using labelled reagent, after labelled reagent (LabelingReagent) tubule is quickly centrifuged, pipe adds 100 μ L1 × PBS and dissolves labelled reagent powder, blow and beat up and down and labelled reagent is mixed, prepare into 1 × labelled reagent solution.
2) in the centrifuge tube equipped with 35ul sample, add 1 × labelled reagent solution and the 155ul labelling buffer of 22ul.Quickly mixing, incubated at room 30min on shaking table, every 5min flicks centrifuge tube, hybrid reaction reagent.
3), after hatching 30min, upper step reactant liquor adds 3 μ L stop buffer (StopSolution)；
4) separately sampled product have added each 100 μ L of sample after stop buffer and have added in Dialysis tubings, then in the 1 × PBS (pH=8) of 4000mL 4 DEG C dialyse while stirring.Dialysis solution is changed once in 3 hours in interval.Dialyse three times and collect sample later.
3, being completely dried of slide chip
By slide chip (Biotinlabel-basedhumanantibodyarray1and2) take out from box, after equilibrium at room temperature 20-30min, packaging bag is opened, open sealing strip, then chip is placed on vacuum desiccator or drying at room temperature 1-2 hour.
4, close and hatch
1) each chip hole adds the Block buffer (BlockingBuffer) of 100 μ L, room temperature shaker is hatched 1h, it is to avoid produce bubble；
2) pump confining liquid, each hole is added sample after 100 μ L dialyse, one sample of an array, 4 DEG C of oscillation incubation 12-16h.
3) clean
Use ThermoScientificWellwashVersa chip to wash trigger and clean slide, it is divided into two steps: be first carried out with 1 × washing liquid I (WashBufferI) (diluting 20 × washing liquid I with deionized water to obtain), 1 × washing liquid I of every hole 250 μ L, clean 5 times, shaking 10s, impact strength selects height every time；Then using 1 × washing liquid II passage instead to be carried out, 1 × washing liquid II (WashBufferII) (diluting 20 × washing liquid II with deionized water to obtain) of every hole 250 μ L, clean 3 times, shake 10s every time, impact strength selects height.
4) 1 × washing liquid II is pumped, the Cy3equivalent room temperature lucifuge oscillation incubation of every hole addition 100uL confining liquid 1500 dilution 2 hours.
5) according to step 3) and 4) wash slide.
5, fluoroscopic examination
Adopt laser scanner such as AxonGenePix to scan signal, adopt Cy3 or green channel (stimulating frequency=532nm), scanner: the GenePix4000BMicroarrayScanner (place of production: MolecularDevices, LLC；1311OrleansDriveSunnyvale, CA94089-1136UnitedStates), sweep parameter: PMT: high intensity, Wavelengh:532nm；Resolution:10um.
Adopt instrument to carry analysis software and extract data, adopt the data analysis software of AAH-BLG-CUST to carry out data analysis.After data analysis, the Cerberus protein concentration of each sample can be immediately arrived at.
Three, interpretation of result
Difference analysis: adopt SPSS17.0 that experimental group (patients with lung cancer) and matched group (people taking physical examination) are carried out statistical analysis.
Picture making: complete with GraphPadPrism5.0 software.
Four, the dependency of the expression of Cerberus and pulmonary carcinoma
Patients with lung cancer is shown in Fig. 1 with the expression testing result of Cerberus in normal healthy controls serum.
As seen from Figure 1, the change of serum C erberus Average expression level of patients with lung cancer is 2020pg/ml, the change of serum C erberus Average expression level of normal healthy controls is 750pg/ml, Cerberus patients with lung cancer in early days significantly raises, compared with normal healthy controls group, Cerberus expression difference has statistical significance (P < 0.05).
As can be seen from the above results, compared with normal population, the Cerberus expression of early stage of lung cancer patient significantly raises (P < 0.05), illustrate that pulmonary carcinoma and Cerberus expression are proportionate, the high expressed of Cerberus can significantly improve the probability suffering from pulmonary carcinoma, therefore, it can the expression of Cerberus by detecting crowd to be checked, by Susceptible population's examination of pulmonary carcinoma out.
Embodiment 2 present invention detects composition and the using method thereof of the test kit of blood Cerberus expression
One, the composition of Cerberus detection kit
Detection kit (30 person-portion):
Two, the using method of Cerberus detection kit
Using method is as follows:
1, sample dialysis
Extract the blood of patients with lung cancer and normal healthy controls, after EDTA anticoagulant centrifugal (1200rpm, 10min), carry out second time centrifugal (3000rpm, 15min) by after supernatant absorption, draw the supernatant after second time is centrifuged and blood plasma, as detection specimen ,-80 DEG C of preservations after subpackage.
Plasma sample needs to utilize Dialysis tubing to dialyse before biotin labeling.Separately sampled product 100 μ L joins in Dialysis tubing, then in the 1 × PBS (pH=8) of 4000mL 4 DEG C dialyse while stirring.Dialysis solution is changed once in interval 3 hours, and collection sample of dialyse after three times is to 1.5mL centrifuge tube.
The preparation of note: 1 × PBS: 1.0gKCl, 40gNaCl, 1.0gKH2PO4,5.75gNa2HPO4, with 4,500ml deionized water dissolving, regulate pH=8.0 with 1MNaOH, is finally settled to 5,000ml with deionized water.
2, biotin labeling sample
Process at whole biotin labeling sample, it is to avoid any reagent is subject to the pollution of amine substance or sodium azide.
1) before using labelled reagent, after labelled reagent (LabelingReagent) tubule is quickly centrifuged, pipe adds 100 μ L1 × PBS and dissolves labelled reagent powder, blow and beat up and down and labelled reagent is mixed, prepare into 1 × labelled reagent solution.
2) in the centrifuge tube equipped with 35ul sample, add 1 × labelled reagent solution and the 155ul labelling buffer of 22ul.Quickly mixing, incubated at room 30min on shaking table, every 5min flicks centrifuge tube, hybrid reaction reagent.
3), after hatching 30min, upper step reactant liquor adds 3 μ L stop buffer (StopSolution)；
4) separately sampled product have added each 100 μ L of sample after stop buffer and have added in Dialysis tubings, then in the 1 × PBS (pH=8) of 4000mL 4 DEG C dialyse while stirring.Dialysis solution is changed once in 3 hours in interval.Dialyse three times and collect sample later.
3, being completely dried of slide chip
By slide chip (Biotinlabel-basedhumanantibodyarray1and2) take out from box, after equilibrium at room temperature 20-30min, packaging bag is opened, open sealing strip, then chip is placed on vacuum desiccator or drying at room temperature 1-2 hour.
4, close and hatch
1) each chip hole adds the Block buffer (BlockingBuffer) of 100 μ L, room temperature shaker is hatched 1h, it is to avoid produce bubble；
2) pump confining liquid, each hole is added sample after 100 μ L dialyse, one sample of an array, 4 DEG C of oscillation incubation 12-16h.
3) clean
Use ThermoScientificWellwashVersa chip to wash trigger and clean slide, it is divided into two steps: be first carried out with 1 × washing liquid I (WashBufferI) (diluting 20 × washing liquid I with deionized water to obtain), 1 × washing liquid I of every hole 250 μ L, clean 5 times, shaking 10s, impact strength selects height every time；Then using 1 × washing liquid II passage instead to be carried out, 1 × washing liquid II (WashBufferII) (diluting 20 × washing liquid II with deionized water to obtain) of every hole 250 μ L, clean 3 times, shake 10s every time, impact strength selects height.
4) 1 × washing liquid II is pumped, the Cy3equivalent room temperature lucifuge oscillation incubation of every hole addition 100uL confining liquid 1500 dilution 2 hours.
5) according to step 3) and 4) wash slide.
5, fluoroscopic examination
Adopt laser scanner such as AxonGenePix to scan signal, adopt Cy3 or green channel (stimulating frequency=532nm), scanner: the GenePix4000BMicroarrayScanner (place of production: MolecularDevices, LLC；1311OrleansDriveSunnyvale, CA94089-1136UnitedStates), sweep parameter: PMT: high intensity, Wavelengh:532nm；Resolution:10um.
Adopt instrument to carry analysis software and extract data, adopt the data analysis software of AAH-BLG-CUST to carry out data analysis.After data analysis, the Cerberus protein concentration of each sample can be immediately arrived at.
To sum up, test kit of the present invention is by detecting the expression of Cerberus, examination crowd to be checked can suffer from the risk of pulmonary carcinoma: if the expression of Cerberus is high, the risk then suffering from pulmonary carcinoma is high, if the expression of Cerberus is low, then the risk suffering from pulmonary carcinoma is low, can be used for the auxiliary diagnosis of clinical pulmonary carcinoma, taking the remedy measures being correlated with or decision-making to provide effective foundation for patient, potential applicability in clinical practice is good.
Claims (8)
1. a screening lung cancer test kit, it is characterised in that: it includes the optional reagent for detecting Cerberus expression.
2. kit for screening according to claim 1, it is characterised in that: described reagent is for detecting the reagent of Cerberus expression in serum.
3. kit for screening according to claim 1 and 2, it is characterised in that: the reagent of described detection Cerberus expression is protein chip detection method reagent.
4. kit for screening according to claim 1 and 2, it is characterised in that: the reagent of described detection Cerberus expression is ELISA detection method reagent or WesternBlot detection method reagent.
5. the reagent of detection Cerberus expression purposes in preparing screening lung cancer reagent.
6. purposes according to claim 5, it is characterised in that: described reagent is for detecting the reagent of Cerberus expression in serum.
7. the purposes according to claim 5 or 6, it is characterised in that: the reagent of described detection Cerberus expression is protein chip detection method reagent.
8. the purposes according to claim 5 or 6, it is characterised in that: the reagent of described detection Cerberus expression is ELISA detection method reagent or WesternBlot detection method reagent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610210301.6A CN105759056B (en) | 2016-04-06 | 2016-04-06 | Lung cancer screening kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610210301.6A CN105759056B (en) | 2016-04-06 | 2016-04-06 | Lung cancer screening kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105759056A true CN105759056A (en) | 2016-07-13 |
| CN105759056B CN105759056B (en) | 2017-11-14 |
Family
ID=56334206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610210301.6A Active CN105759056B (en) | 2016-04-06 | 2016-04-06 | Lung cancer screening kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105759056B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106546739A (en) * | 2016-10-18 | 2017-03-29 | 石永录 | A kind of screening lung cancer test kit |
| CN106916900A (en) * | 2017-05-05 | 2017-07-04 | 成都医学院第附属医院 | A kind of kit of examination cancer brain metastes |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998049296A1 (en) * | 1997-04-29 | 1998-11-05 | Regeneron Pharmaceuticals, Inc. | Human cerberus protein |
| WO2008048120A2 (en) * | 2006-10-17 | 2008-04-24 | Synergenz Bioscience Limited | Methods and compositions for assessment of pulmonary function and disorders |
| CN101589137A (en) * | 2005-03-31 | 2009-11-25 | 斯丹姆涅恩有限公司 | Amnion-derived cell compositions, methods of making and uses thereof |
-
2016
- 2016-04-06 CN CN201610210301.6A patent/CN105759056B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998049296A1 (en) * | 1997-04-29 | 1998-11-05 | Regeneron Pharmaceuticals, Inc. | Human cerberus protein |
| CN101589137A (en) * | 2005-03-31 | 2009-11-25 | 斯丹姆涅恩有限公司 | Amnion-derived cell compositions, methods of making and uses thereof |
| WO2008048120A2 (en) * | 2006-10-17 | 2008-04-24 | Synergenz Bioscience Limited | Methods and compositions for assessment of pulmonary function and disorders |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106546739A (en) * | 2016-10-18 | 2017-03-29 | 石永录 | A kind of screening lung cancer test kit |
| CN106916900A (en) * | 2017-05-05 | 2017-07-04 | 成都医学院第附属医院 | A kind of kit of examination cancer brain metastes |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105759056B (en) | 2017-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105785036A (en) | Lung cancer screening kit | |
| Li et al. | Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma | |
| CN104471402A (en) | Biomarkers for triple negative breast cancer | |
| CN105572353B (en) | A kind of antibody chip kit for detecting liver cancer marker | |
| CN104650234B (en) | Anti- AKR1B10 protein monoclonal antibodies and its application | |
| CN104316685B (en) | Diacetyl spermine detection kit and preparation method and application thereof | |
| CN110196329A (en) | A kind of cancer of the esophagus early stage combined detection kit | |
| CN109270269A (en) | A kind of fluorescence immune chromatography detection card, kit for the multi-joint detection of early-stage breast cancer | |
| CN104515797A (en) | Breast cancer early stage diagnosis sialoprotein fingerprint model and construction method thereof | |
| CN107255711B (en) | Osteopontin is used to prepare or screens the purposes of acute-on-chronic liver failure diagnostic reagent | |
| CN104345154B (en) | A kind of double-antibody sandwich test kit detecting many tumors relevant " the box-like mark of polypeptide-protein groups " | |
| CN106680515B (en) | It is combined for the polymolecular marker of pulmonary cancer diagnosis | |
| CN105759056A (en) | Lung cancer screening kit | |
| CN106834511A (en) | A kind of kit of the breast cancer detection based on liquid biopsy | |
| CN103954761B (en) | For oophoroma early metaphase quick diagnosis reagent kit and detection method thereof | |
| CN103969453B (en) | Alpha-fetoprotein autoantibody individually or combines the application monitoring mark as diagnosing tumor, curative effect evaluation and recurrence with alpha-fetoprotein | |
| CN105675572B (en) | Lung cancer screening kit | |
| CN105548546B (en) | Lung cancer screening kit | |
| CN108034722A (en) | A kind of lncRNA SGOL1-AS1 are in the application as diagnosing gastric cancer marker | |
| WO2019169857A1 (en) | Application of igg4 detection reagent in preparation of colorectal cancer diagnostic agent | |
| CN106990080B (en) | A kind of kit of the non-small cell lung cancer detection based on liquid biopsy | |
| CN109085359A (en) | Serum protein markers combine the application in colorectal cancer screening and diagnosis and treatment | |
| TWI656344B (en) | Method for screening circulating tumor cells in blood | |
| CN113687076A (en) | Combined detection serum marker for early diagnosis of lung adenocarcinoma and application thereof | |
| Xue et al. | Clinical value of vascular endothelial growth factor combined with interferon-γ in diagnosing malignant pleural effusion and tuberculous pleural effusion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |